Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy
Pharmaceutics · 01.09.2024 · 16 (9) · 1158
DOI: 10.3390/pharmaceutics16091158 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 01.09.2024. Verfasst von Alessandra Giordano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Industrial Engineering, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Theranostics is a growing field that matches diagnostics and therapeutics. In this approach, drugs and techniques are uniquely coupled to diagnose and treat medical conditions synergically or sequentially. By integrating diagnostic and treatment functions in a single platform, the aim of theranostics is to improve precision medicine by tailoring treatments based on real-time information. In this context, lipid-based nanocarriers have attracted great scientific attention due to their biodegradability, biocompatibility, and targeting capabilities. The present review highlights the latest research advances in the field of lipid-based nanocarriers for cancer theranostics, exploring several ways of improving in vivo performance and addressing associated challenges. These nanocarriers have significant potential to create new perspectives in the field of nanomedicine and offer promise for a significant step towards more personalized and precise medicine, reducing side effects and improving clinical outcomes for patients. This review also presents the actual barriers to and the possible challenges in the use of nanoparticles in the theranostic field, such as regulatory hurdles, high costs, and technological integration. Addressing these issues through a multidisciplinary and collaborative approach among institutions could be essential for advancing lipid nanocarriers in the theranostic field. Such collaborations can leverage diverse expertise and resources, fostering innovation and overcoming the complex challenges associated with clinical translation. This approach will be crucial for realizing the full potential of lipid-based nanocarriers in precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Industrial Engineering, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
- Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli, 1, 40136 Bologna, Italy.
ORCID-Profile: Lucia Baldino, Ernesto Reverchon
Zitieren
APA
Giordano, A., Provenza, A. C., Reverchon, G., Baldino, L., & Reverchon, E. (2024). Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy. Pharmaceutics, 16(9), 1158. https://doi.org/10.3390/pharmaceutics16091158
Vancouver
Giordano A, Provenza AC, Reverchon G, Baldino L, Reverchon E. Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy. Pharmaceutics. 2024;16(9):1158. doi:10.3390/pharmaceutics16091158
BibTeX
@article{Giordano2024,
author = {Giordano, Alessandra and Provenza, Anna Chiara and Reverchon, Giorgio and Baldino, Lucia and Reverchon, Ernesto},
title = {Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {9},
pages = {1158},
doi = {10.3390/pharmaceutics16091158}
}
EUVIMED